Brokerages Set Enovis Corporation (NYSE:ENOV) PT at $45.17

Shares of Enovis Corporation (NYSE:ENOV) have received a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $45.1667.

ENOV has been the subject of several analyst reports. William Blair initiated coverage on shares of Enovis in a report on Friday, April 17th. They set an “outperform” rating for the company. Needham & Company LLC lifted their price target on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a report on Thursday, February 26th. BTIG Research lifted their price target on shares of Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Zacks Research raised shares of Enovis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 4th. Finally, Evercore reissued an “outperform” rating and set a $36.00 price target on shares of Enovis in a report on Friday, May 8th.

Enovis Trading Down 6.9%

Shares of ENOV stock opened at $24.32 on Friday. Enovis has a 12-month low of $21.00 and a 12-month high of $36.82. The company has a market capitalization of $1.40 billion, a P/E ratio of -1.22 and a beta of 1.41. The firm has a 50-day moving average price of $23.93 and a 200 day moving average price of $25.56. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The firm had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. During the same period last year, the firm posted $0.81 EPS. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts forecast that Enovis will post 3.65 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Oliver Engert acquired 1,000 shares of the stock in a transaction on Friday, February 27th. The stock was purchased at an average price of $25.50 per share, for a total transaction of $25,500.00. Following the transaction, the insider owned 43,640 shares of the company’s stock, valued at $1,112,820. The trade was a 2.35% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders have bought 5,000 shares of company stock valued at $121,983. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Enovis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC increased its position in Enovis by 11.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 757,673 shares of the company’s stock valued at $20,086,000 after acquiring an additional 78,497 shares in the last quarter. Impax Asset Management Group plc increased its position in Enovis by 47.5% in the 3rd quarter. Impax Asset Management Group plc now owns 310,630 shares of the company’s stock valued at $9,425,000 after acquiring an additional 100,000 shares in the last quarter. Vanguard Group Inc. increased its position in Enovis by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company’s stock valued at $197,945,000 after acquiring an additional 125,460 shares in the last quarter. Invenomic Capital Management LP increased its position in Enovis by 22.7% in the 3rd quarter. Invenomic Capital Management LP now owns 712,669 shares of the company’s stock valued at $21,622,000 after acquiring an additional 131,705 shares in the last quarter. Finally, Deroy & Devereaux Private Investment Counsel Inc. acquired a new stake in Enovis in the 4th quarter valued at about $2,929,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.